Document Detail

Impact of endothelin-1 Lys198Asn polymorphism on coronary artery disease and endorgan damage in hypertensives.
MedLine Citation:
PMID:  18923236     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Endothelin is the most potent endogenous vasoconstrictor and is involved in several vascular disorders such as arterial hypertension. Its intense interaction with other vasoactive hormone systems revealed the consideration about the endothelin gene as an interesting candidate for influencing the development of essential hypertension and hypertensive endorgan damage. The purpose of this study was to investigate the role of endothelin-1 Lys198Asn polymorphism in patients with severe arterial hypertension as well as associated endorgan damages. METHODS: In 400 hypertensive patients and 150 normotensive controls we examined the endothelin-1 Lys198Asn polymorphism by DNA sequencing and patients were divided according to their genotype (GG, GT, and TT). Moreover, the frequency of endothelin-1 Lys198Asn polymorphism was investigated with respect to the prevalence of several actual or historical endorgan damages (renal disorder, coronary artery disease, vascular events, vascular damage, and congestive heart failure) in hypertensive patients. RESULTS: Genotype distribution for endothelin-1 Lys198Asn polymorphism was 57.3% (GG), 41.3% (GT), and 1.43% (TT) in normotensive individuals; and in hypertensive individuals was 54.75% (GG), 43% (GT) and 2.25% (TT). Genotype distribution was unaffected in patients with severe hypertension, renal disorder, vascular events, vascular damage, and congestive heart failure. We, however, found a significant difference in hypertensive individuals with coronary artery disease and TT genotype (P=0.004). CONCLUSION: Homozygous TT carrier contributes to a higher prevalence of coronary artery disease, especially for three-vessel disease in hypertensive individuals. Thus, the polymorphism at position 198 could serve as a possibility to differentiate high-risk subgroups in the heterogeneous population of hypertensive patients.
Aron Frederik Popov; Egbert Godehard Schulz; Jose Hinz; Jan Dieter Schmitto; Ralf Seipelt; Michael Johann Koziolek; Albert Rosenberger; Friedrich Albert Schoendube; Gerhard Anton Müller
Related Documents :
18923236 - Impact of endothelin-1 lys198asn polymorphism on coronary artery disease and endorgan d...
10536906 - Migraine associated bilateral intracerebral haemorrhages.
20194816 - Systemic sclerosis-associated pulmonary arterial hypertension.
20560976 - The management of acute pulmonary arterial hypertension.
15253256 - Multicenter randomized prospective trial comparing a pre-cuffed polytetrafluoroethylene...
3066916 - Vertebral artery compression as an adjunct to transcutaneous doppler ultrasound examina...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Coronary artery disease     Volume:  19     ISSN:  0954-6928     ISO Abbreviation:  Coron. Artery Dis.     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-10-16     Completed Date:  2009-01-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9011445     Medline TA:  Coron Artery Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  429-34     Citation Subset:  IM    
Department of Thoracic Cardiovascular Surgery, University of Göttingen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Atherosclerosis / genetics
Case-Control Studies
Coronary Artery Disease / genetics*
Endothelin-1 / genetics*
Gene Frequency
Genetic Predisposition to Disease
Heart Failure / genetics
Hypertension / complications,  genetics*
Kidney Diseases / genetics
Middle Aged
Polymorphism, Genetic*
Risk Factors
Severity of Illness Index
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease.
Next Document:  Effect of aortic pulse and fractional pulse pressures on early patency of sapheneous vein grafts.